C A Rodriguez1, S Sasse1, K A Yuengling2, S Azzawi1, M C Becerra3, C M Yuen3. 1. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA. 2. Mailman School of Public Health, Columbia University, New York, New York, USA. 3. Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Global Health Equity, Brigham & Women's Hospital, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: To describe mandates and policy gaps in tuberculosis (TB) contact investigation and management. DESIGN: We conducted a systematic review of national TB policy documents obtained using a systematic internet search and by contacting national TB programs. We included policies published in English, Spanish, and French, and abstracted data using a standardized form. RESULTS: We reviewed policy documents for 68 of 216 (31%) countries and territories. All countries recommended performing contact investigations, but 40% did not specify how contacts enter the health system for evaluation or who was responsible for this process. All countries recommended preventive therapy for contacts, but in 14 (21%) countries only young children were eligible. While four preventive therapy regimens exist, 48 (71%) countries recommended only isoniazid monotherapy. In addition, 28 (41%) countries lacked guidance on whether to give preventive therapy to contacts exposed to drug-resistant TB. Policies in 28 (41%) countries lacked recommendations for managing contacts with the human immunodeficiency virus (HIV) after new TB exposure. CONCLUSION: Policies recommending contact investigation and preventive therapy for contacts are widespread, but policy gaps exist in the areas of ensuring accountability and the management of vulnerable populations such as people living with HIV and those exposed to drug-resistant TB.
OBJECTIVE: To describe mandates and policy gaps in tuberculosis (TB) contact investigation and management. DESIGN: We conducted a systematic review of national TB policy documents obtained using a systematic internet search and by contacting national TB programs. We included policies published in English, Spanish, and French, and abstracted data using a standardized form. RESULTS: We reviewed policy documents for 68 of 216 (31%) countries and territories. All countries recommended performing contact investigations, but 40% did not specify how contacts enter the health system for evaluation or who was responsible for this process. All countries recommended preventive therapy for contacts, but in 14 (21%) countries only young children were eligible. While four preventive therapy regimens exist, 48 (71%) countries recommended only isoniazid monotherapy. In addition, 28 (41%) countries lacked guidance on whether to give preventive therapy to contacts exposed to drug-resistant TB. Policies in 28 (41%) countries lacked recommendations for managing contacts with the human immunodeficiency virus (HIV) after new TB exposure. CONCLUSION: Policies recommending contact investigation and preventive therapy for contacts are widespread, but policy gaps exist in the areas of ensuring accountability and the management of vulnerable populations such as people living with HIV and those exposed to drug-resistant TB.
Authors: R Ryan Lash; Patrick K Moonan; Brittany L Byers; Robert A Bonacci; Kimberly E Bonner; Matthew Donahue; Catherine V Donovan; Heather N Grome; Julia M Janssen; Reed Magleby; Heather P McLaughlin; James S Miller; Caroline Q Pratt; Jonathan Steinberg; Kate Varela; Greta L Anschuetz; Paul R Cieslak; Veronica Fialkowski; Aaron T Fleischauer; Clay Goddard; Sara Jo Johnson; Michelle Morris; Jill Moses; Allison Newman; Lauren Prinzing; Alana C Sulka; Puthiery Va; Matthew Willis; John E Oeltmann Journal: JAMA Netw Open Date: 2021-06-01
Authors: Kathryn J Snow; Lisa J Nelson; Charalambos Sismanidis; Susan M Sawyer; Stephen M Graham Journal: Epidemiol Infect Date: 2018-04-15 Impact factor: 4.434
Authors: Peter J Dodd; Courtney M Yuen; Mercedes C Becerra; Paul Revill; Helen E Jenkins; James A Seddon Journal: Lancet Glob Health Date: 2018-09-25 Impact factor: 26.763
Authors: Courtney M Yuen; Ana K Millones; Carmen C Contreras; Leonid Lecca; Mercedes C Becerra; Salmaan Keshavjee Journal: PLoS One Date: 2019-05-17 Impact factor: 3.240
Authors: Patrick K Moonan; Nicola M Zetola; James L Tobias; Joyce Basotli; Rosanna Boyd; Eleanor S Click; Mbatshi Dima; Othusitse Fane; Alyssa M Finlay; Matsiri Ogopotse; Xiao J Wen; Chawangwa Modongo; John E Oeltmann Journal: Emerg Infect Dis Date: 2020-05 Impact factor: 6.883
Authors: Ken Warria; Peter Nyamthimba; Alex Chweya; Janet Agaya; Millicent Achola; Mary Reichler; Jessica Cowden; Charles M Heilig; Martien W Borgdorff; Kevin P Cain; Courtney M Yuen Journal: Trop Med Int Health Date: 2020-04-06 Impact factor: 3.918
Authors: Monadil H Ali; Alian A Alrasheedy; Dan Kibuule; Mohamed Azmi Hassali; Brian Godman; Mohammed F Abdelwahab; Raef Y Abbadi Journal: J Clin Tuberc Other Mycobact Dis Date: 2019-09-06
Authors: Ruoran Li; Francesco Nordio; Chuan-Chin Huang; Carmen Contreras; Roger Calderon; Rosa Yataco; Jerome T Galea; Zibiao Zhang; Mercedes C Becerra; Leonid Lecca; Megan B Murray Journal: Clin Infect Dis Date: 2020-11-05 Impact factor: 9.079